Prs17 - Budget Impact Analysis of the Use of Umeclidinium Bromide/Vilanterol 62.5/25 MCG in the Treatment of Chronic Obstructive Pulmonary Disease in Spain
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2411
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV